Equities research analysts at Citigroup assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in a note issued to investors on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $31.00 price target on the biotechnology company’s stock. Citigroup’s price target suggests a potential upside of 32.99% from the company’s previous […]
Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “market outperform” rating reissued by stock analysts at JMP Securities in a research note issued to investors on Thursday, Benzinga reports. They presently have a $27.00 target price on the biotechnology company’s stock. JMP Securities’ target price indicates a potential upside of 14.89% from the company’s […]
Great West Life Assurance Co. Can trimmed its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 11.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 223,637 shares of the biotechnology company’s stock after selling 28,634 shares during the period. […]
Covestor Ltd Sells 8,318 Shares of Exelixis, Inc. (NASDAQ:EXEL) tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Edgestream Partners L.P. Purchases New Shares in Exelixis, Inc. (NASDAQ:EXEL) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the target of some unusual options trading activity on Friday. Investors acquired 3,824 put options on the stock. This is an increase of approximately 102% compared to the average volume of 1,890 put options. Insider Activity at Exelixis In related news, EVP Dana Aftab sold 4,600 shares […]
Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Stock analysts at William Blair upped their Q2 2024 earnings estimates for shares of Exelixis in a research report issued on Wednesday, November 1st. William Blair analyst A. Hsieh now anticipates that the biotechnology company will earn $0.21 per share for the quarter, up from their previous forecast […]
Exelixis (NASDAQ:EXEL – Free Report) had its price objective increased by Morgan Stanley from $22.00 to $23.00 in a research note published on Thursday, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. Barclays lowered their […]
William Blair restated their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report published on Monday morning, RTT News reports. William Blair also issued estimates for Exelixis’ Q3 2023 earnings at ($0.05) EPS and FY2023 earnings at $0.45 EPS. EXEL has been the topic of several other research reports. […]
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price traded down 6.1% on Monday . The company traded as low as $19.12 and last traded at $19.83. 2,044,579 shares changed hands during trading, a decline of 23% from the average session volume of 2,657,925 shares. The stock had previously closed at $21.11. Wall Street Analyst […]